HIGHLIGHTS
SUMMARY
Subsequent analysis revealed that a significantly higher percentage of patients receiving radium-223 experienced meaningful HR-QoL improvement when compared to patients treated with placebo. Studies evaluating HR-QoL, psychological distress, and fatigue in mCRPC patients treated with radium-223 in daily practice are lacking. The aim of this study was to evaluate cancer-specific and bone metastases-related HR-QoL, psychological distress, and fatigue in mCRPC patients before, during and after treatment with radium223 in daily practice. The authors hypothesized that there would be different HR-QoL trajectories between patients who were able . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.